US 11957754
Clinical formulations
granted A61KA61K31/7004A61K31/728
Quick answer
US patent 11957754 (Clinical formulations) held by Astellas Institute for Regenerative Medicine expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Astellas Institute for Regenerative Medicine
- Grant date
- Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 29
- CPC classes
- A61K, A61K31/7004, A61K31/728, A61K33/06, A61K33/14